NASDAQ:RIGL

Rigel Pharmaceuticals - RIGL Stock Forecast, Price & News

$0.83

+0.15 (+21.95%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.82
▼
$0.99
50-Day Range: $0.67
▼
$1.22
52-Week Range: $0.64
▼
$3.52

Volume: 60.09 million shs
Average Volume: 1.37 million shs
Market Capitalization: $144.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.96

Rigel Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.43 Rating Score
Upside/Downside: 374.9% Upside
$3.96 Price Target
Short Interest: Healthy
3.19% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.80
Based on 14 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.49) to ($0.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

255th out of 1,034 stocks

Pharmaceutical Preparations Industry

107th out of 502 stocks

3.2

Analyst's Opinion

Consensus Rating
Rigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.96, Rigel Pharmaceuticals has a forecasted upside of 374.9% from its current price of $0.83.
Amount of Analyst Coverage
Rigel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.19% of the outstanding shares of Rigel Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Rigel Pharmaceuticals has recently decreased by 7.55%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Rigel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rigel Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RIGL.

3.2

News and Social Media Coverage

News Sentiment
Rigel Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Rigel Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 10 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
13 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 333% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.43% of the stock of Rigel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
80.94% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rigel Pharmaceuticals are expected to grow in the coming year, from ($0.49) to ($0.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rigel Pharmaceuticals is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rigel Pharmaceuticals is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Rigel Pharmaceuticals (NASDAQ:RIGL) Stock

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RIGL Stock News Headlines

December 4, 2022 | americanbankingnews.com

Rigel Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RIGL)

December 3, 2022 | finance.yahoo.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) insiders have a reason to boast after seeing a US$145k addition to their US$688k investment

December 2, 2022 | seekingalpha.com

Rigel upgraded at Citi on bullish outlook for new leukemia drug

December 2, 2022 | finance.yahoo.com

Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia

December 2, 2022 | investorplace.com

Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News

December 2, 2022 | marketwatch.com

Rigel Pharmaceuticals Shares Leap Premarket on FDA OK of Rezlidhia >RIGL

December 2, 2022 | finance.yahoo.com

Rigel stock soars after FDA approves leukemia treatment, 2 days after receiving delisting notice

December 2, 2022 | markets.businessinsider.com

Rigel : FDA Oks REZLIDHIA For Treatment Of R/R Acute Myeloid Leukemia With Susceptible IDH1 Mutation

December 1, 2022 | finance.yahoo.com

Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

November 12, 2022 | finance.yahoo.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst institutional investors who own 72%

November 10, 2022 | finance.yahoo.com

Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology

November 4, 2022 | seekingalpha.com

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Call Transcript

November 3, 2022 | markets.businessinsider.com

Rigel Pharmaceuticals Inc. Q3 Loss decreases, beats estimates

November 3, 2022 | finance.yahoo.com

Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update

November 3, 2022 | finance.yahoo.com

Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition

November 2, 2022 | seekingalpha.com

Rigel Pharma gains as analysts play down setback for COVID-19 therapy

November 2, 2022 | finance.yahoo.com

Another Clinical Trial Setback For Rigel Pharma's Lead Program, This Time For COVID-19

October 27, 2022 | finance.yahoo.com

Rigel Announces Conference Call and Webcast to Report Third Quarter 2022 Financial Results and Business Update

October 18, 2022 | seekingalpha.com

RIGL Rigel Pharmaceuticals, Inc.

October 11, 2022 | msn.com

Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs

October 11, 2022 | finance.yahoo.com

Rigel Pharma Drops FDA Submission Plans For Expanded Use Of Its Lead Product

October 11, 2022 | nasdaq.com

Rigel Pharma Does Not Expect To File SNDA For Fostamatinib For Treatment Of WAIHA

October 10, 2022 | finance.yahoo.com

Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

October 10, 2022 | finance.yahoo.com

Why Peninsula-based drug maker Rigel is cutting 16% of its workforce

September 21, 2022 | finance.yahoo.com

Calculating The Fair Value Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RIGL Company Calendar

Last Earnings: 11/03/2022
Today: 12/04/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/07/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:RIGL
CUSIP: 76655960
CIK: 1034842
Web: www.rigel.com
Phone: (650) 624-1100
Fax: 650-624-1101
Employees: 165
Year Founded: 1996

Price Target and Rating

Average Stock Price Forecast: $3.96
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +374.9%
Consensus Rating: Hold
Rating Score (0-4): 2.43
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,910,000.00
Net Margins: -92.44%
Pretax Margin: -92.51%
Return on Equity: -2,419.00%
Return on Assets: -59.01%

Debt

Debt-to-Equity Ratio: 4.39
Current Ratio: 2.34
Quick Ratio: 2.19

Sales & Book Value

Annual Sales: $149.24 million
Price / Sales: 0.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.11) per share
Price / Book: -7.58

Miscellaneous

Outstanding Shares: 172,840,000
Free Float: 161,723,000
Market Cap: $144.06 million
Optionable: Optionable
Beta: 1.25

Social Links

Key Executives

Mr. Raul R. Rodriguez (Age 61)
Pres, CEO & Director
Comp: $979.34k

Mr. Dean L. Schorno CPA (Age 59)
Exec. VP & CFO
Comp: $623.46k

Ms. Dolly A. Vance (Age 57)
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
Comp: $810.06k

Dr. Wolfgang Dummer M.D. (Age 56)
Ph.D., Exec. VP & Chief Medical Officer
Comp: $644.05k

Mr. David A. Santos (Age 59)
Exec. VP & Chief Commercial Officer
Comp: $600.64k

Mr. Joseph Lasaga (Age 47)
Exec. VP of Corp. Devel.

Ms. Julie Patel
Sr. VP of HR

Dr. Esteban S. Masuda (Age 60)
Exec. VP of Research

Mr. Tarek Sallam
VP of Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RIGL Stock - Frequently Asked Questions

Should I buy or sell Rigel Pharmaceuticals stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares.
View RIGL analyst ratings or view top-rated stocks.
What is Rigel Pharmaceuticals' stock price forecast for 2023?: 7 equities research analysts have issued 1 year target prices for Rigel Pharmaceuticals' stock. Their RIGL share price forecasts range from $1.00 to $15.00. On average, they predict the company's share price to reach $3.96 in the next twelve months. This suggests a possible upside of 374.9% from the stock's current price.
View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts.
How have RIGL shares performed in 2022?: Rigel Pharmaceuticals' stock was trading at $2.65 at the start of the year. Since then, RIGL shares have decreased by 68.5% and is now trading at $0.8335.
View the best growth stocks for 2022 here.
When is Rigel Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RIGL earnings forecast.
How were Rigel Pharmaceuticals' earnings last quarter?: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The biotechnology company earned $22.41 million during the quarter, compared to the consensus estimate of $22.76 million. Rigel Pharmaceuticals had a negative trailing twelve-month return on equity of 2,419.00% and a negative net margin of 92.44%.
What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?: 6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Rigel Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).
What is Rigel Pharmaceuticals' stock symbol?: Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."
Who are Rigel Pharmaceuticals' major shareholders?: Rigel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.36%), Vanguard Group Inc. (6.91%), State Street Corp (2.24%), Armistice Capital LLC (2.00%), Jacobs Levy Equity Management Inc. (1.71%) and Assenagon Asset Management S.A. (1.55%).
View institutional ownership trends.
How do I buy shares of Rigel Pharmaceuticals?: Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Rigel Pharmaceuticals' stock price today?: One share of RIGL stock can currently be purchased for approximately $0.83.
How much money does Rigel Pharmaceuticals make?: Rigel Pharmaceuticals (NASDAQ:RIGL) has a market capitalization of $144.06 million and generates $149.24 million in revenue each year. The biotechnology company earns $-17,910,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.
How many employees does Rigel Pharmaceuticals have?: The company employs 165 workers across the globe.
How can I contact Rigel Pharmaceuticals?: Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rigel.com. The biotechnology company can be reached via phone at (650) 624-1100, via email at ir@rigel.com, or via fax at 650-624-1101.

This page (NASDAQ:RIGL) was last updated on 12/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial